CAR-T cell therapy offers a potentially paradigm-changing new treatment for multiple myeloma. Additionally, CAR-T toxicity is may be more manageable than other treatments. While cytokine release syndrome (CRS) is common in CAR-T trials, these are generally short-lived and managed with standard therapies. There are various ongoing clinical trials using CAR-T cell technology to target myeloma antigens, and this podcast discusses the use of B-cell maturation antigen (BCMA) CAR-T.
In this podcast, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, chairs a discussion with Edward Stadtmauer, MD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, and Krina Patel, MD, MSc, MD Anderson Cancer Center, Houston, TX, on the potential of CAR-T therapy in the treatment of multiple myeloma.
The post CAR T-cell therapy & multiple myeloma: past, present & future appeared first on VJHemOnc.
